BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations of additional analyses from the FALCON clinical trial (NCT02578940) of...
Orphazyme A/S Also Completed a Major New Capital Raise of $110 Million to Cover its Expansion CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement [11-February-2020] LOS ANGELES, Feb. 11,...
Elicio Therapeutics, a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology...
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences GroupGroup, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...
– Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease – Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF time sustained for at least two years EMERYVILLE,...
Email
Text